<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="123789">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01491022</url>
  </required_header>
  <id_info>
    <org_study_id>20110173</org_study_id>
    <nct_id>NCT01491022</nct_id>
  </id_info>
  <brief_title>A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease</brief_title>
  <official_title>A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Acorda Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of AMPYRA on a number of symptoms in
      Parkinson's disease. AMPYRA is a medication approved by FDA for gait dysfunction in multiple
      sclerosis. There are multiple studies to suggest that persons with multiple sclerosis
      benefit from this medication and have major improvements in gait after taking this
      medication. However, this medication was never studied in Parkinson's disease. This study
      aims to learn about possible benefits of AMPYRA in Parkinson's disease (PD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with Parkinson's disease will be randomly assigned to two groups. One group will
      receive Ampyra first for 4 weeks, followed by 2 weeks break and than 4 weeks placebo while
      the second group will first receive placebo and then Ampyra.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>gait velocity and stride length.</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>The primary outcome measure will be the change in gait velocity and stride length as measured with by 3-dimensional gait analysis system.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>United Parkinson's Disease Rating Scale score(UPDRS) ,</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>change in UPDRS score (motor)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freezing of Gait Questionnaire (FOGQ)</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>change in FOGQ score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed Up and Go (TUG) score</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>changes in time required to perform TUG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed 25-foot Walk test (T25FW)</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>changes in time required to perform T25FW.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Gait Disorders</condition>
  <arm_group>
    <arm_group_label>Ampyra</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ampyra 10 mg po BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalfampridine</intervention_name>
    <description>10 mg po bid for 4 weeks</description>
    <arm_group_label>Ampyra</arm_group_label>
    <other_name>AMPYRA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic PD with stage Hoehn and Yahr Stage&gt;1-3 and with gait freezing or postural
             instability.

          -  On stable dosage dopamine agonist/levodopa, and expected to remain on the same dosage
             of treatment for the duration of study

          -  Age less than 80, onset of disease at age more than 45.

          -  Able to give consent

        Exclusion Criteria:

          -  Past medical history of seizures,

          -  History of renal insufficiency,

          -  History of cardiac arrhythmia,

          -  Severe arthritis,

          -  Women of childbearing potential,

          -  Cognitive impairment

          -  Age more than 80.

          -  PD patients stage 4 H&amp;Y

          -  PD patient with recent introduction of dopamine agonist or IMAO B

          -  PD patients participating in other studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 11, 2016</lastchanged_date>
  <firstreceived_date>December 8, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Corneliu C Luca</investigator_full_name>
    <investigator_title>Neurology Instructor</investigator_title>
  </responsible_party>
  <keyword>parkinson's</keyword>
  <keyword>gait dysfunction</keyword>
  <keyword>ampyra</keyword>
  <keyword>4-aminopyridine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
